BenQ Medical Technology Corporation (TPEX:4116)
Taiwan · Delayed Price · Currency is TWD 41.90
-0.30 (-0.71%)
At close: Feb 11, 2026
BenQ Medical Technology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 5,198 | 4,767 | 4,543 | 4,377 | 1,465 | 1,401 | |
Revenue Growth (YoY) | 11.62% | 4.94% | 3.80% | 198.82% | 4.55% | 1.49% |
Cost of Revenue | 3,554 | 3,319 | 3,199 | 3,129 | 952.31 | 849.22 |
Gross Profit | 1,644 | 1,448 | 1,344 | 1,247 | 512.28 | 551.63 |
Selling, General & Admin | 1,257 | 1,079 | 947.17 | 855.13 | 423.58 | 409.99 |
Research & Development | 37.22 | 36.39 | 31.96 | 39.58 | 39.65 | 44.3 |
Other Operating Expenses | - | - | -1.53 | 0.73 | 0.81 | - |
Operating Expenses | 1,298 | 1,115 | 978.46 | 896.88 | 465.82 | 454.42 |
Operating Income | 346.42 | 333.02 | 365.44 | 350.26 | 46.46 | 97.21 |
Interest Expense | -42.43 | -34.22 | -27.94 | -17.83 | -3.91 | -4.02 |
Interest & Investment Income | 12.79 | 11.23 | 10.21 | 5.24 | 0.69 | 0.8 |
Earnings From Equity Investments | - | - | -57.38 | -125.05 | 1.79 | 4.15 |
Currency Exchange Gain (Loss) | -16.57 | 8.98 | -2.5 | 3.44 | -0.53 | -3.52 |
Other Non Operating Income (Expenses) | 15.82 | 10.91 | 17.15 | 14.28 | 16.56 | 10.4 |
EBT Excluding Unusual Items | 316.04 | 329.91 | 304.98 | 230.33 | 61.06 | 105.03 |
Gain (Loss) on Sale of Investments | 4.45 | - | 5.13 | - | - | - |
Gain (Loss) on Sale of Assets | 15.5 | -0.9 | -0.03 | 3.85 | 0.06 | 0.07 |
Other Unusual Items | 0.06 | 0.37 | 0.09 | 81.57 | 0.66 | 0.57 |
Pretax Income | 336.04 | 329.38 | 310.17 | 315.74 | 61.78 | 105.67 |
Income Tax Expense | 105.09 | 92.13 | 109.91 | 79.15 | 12.75 | 21.55 |
Earnings From Continuing Operations | 230.95 | 237.25 | 200.26 | 236.6 | 49.04 | 84.12 |
Minority Interest in Earnings | -145.16 | -132.42 | -85.68 | -56.35 | -20.2 | -22.07 |
Net Income | 85.79 | 104.83 | 114.58 | 180.24 | 28.84 | 62.05 |
Net Income to Common | 85.79 | 104.83 | 114.58 | 180.24 | 28.84 | 62.05 |
Net Income Growth | -25.72% | -8.51% | -36.43% | 524.98% | -53.52% | -17.71% |
Shares Outstanding (Basic) | 45 | 45 | 45 | 45 | 45 | 45 |
Shares Outstanding (Diluted) | 45 | 45 | 45 | 45 | 45 | 45 |
Shares Change (YoY) | 0.00% | 0.02% | -0.07% | 0.42% | -0.30% | -0.09% |
EPS (Basic) | 1.93 | 2.35 | 2.57 | 4.04 | 0.65 | 1.39 |
EPS (Diluted) | 1.92 | 2.34 | 2.56 | 4.02 | 0.65 | 1.39 |
EPS Growth | -25.56% | -8.59% | -36.32% | 521.20% | -53.44% | -17.26% |
Free Cash Flow | 230.82 | 52.14 | 308.88 | 405.95 | 91.09 | 115.07 |
Free Cash Flow Per Share | 5.15 | 1.16 | 6.89 | 9.05 | 2.04 | 2.57 |
Dividend Per Share | 1.650 | 1.650 | 2.000 | 2.100 | 0.500 | 1.000 |
Dividend Growth | -17.50% | -17.50% | -4.76% | 320.00% | -50.00% | -25.93% |
Gross Margin | 31.63% | 30.38% | 29.58% | 28.50% | 34.98% | 39.38% |
Operating Margin | 6.66% | 6.98% | 8.04% | 8.00% | 3.17% | 6.94% |
Profit Margin | 1.65% | 2.20% | 2.52% | 4.12% | 1.97% | 4.43% |
Free Cash Flow Margin | 4.44% | 1.09% | 6.80% | 9.28% | 6.22% | 8.21% |
EBITDA | 527.53 | 509.07 | 532.15 | 520.51 | 107.71 | 146.02 |
EBITDA Margin | 10.15% | 10.68% | 11.71% | 11.89% | 7.36% | 10.42% |
D&A For EBITDA | 181.11 | 176.05 | 166.72 | 170.24 | 61.25 | 48.81 |
EBIT | 346.42 | 333.02 | 365.44 | 350.26 | 46.46 | 97.21 |
EBIT Margin | 6.66% | 6.98% | 8.04% | 8.00% | 3.17% | 6.94% |
Effective Tax Rate | 31.27% | 27.97% | 35.43% | 25.07% | 20.63% | 20.39% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.